Table 2.
Patient characteristics
| Patient characteristics | On trial (n = 35) | Off trial (n = 2) (unable to dose escalate) |
|
|---|---|---|---|
| Patient 1 | Patient 2 | ||
| Sex | |||
| Female | 18 (51%) | 1 | — |
| Male | 17 (49%) | — | 1 |
| Age, years | 52 | 48 | |
| Median | 69.9 | ||
| Range | 46-86 | ||
| ECOG PS | |||
| 0 | 5 (14.2%) | 1 | 1 |
| 1 | 27 (77.1%) | ||
| 2 | 3 (8.6%) | ||
| Stage | |||
| IIIa | 22 (62.9%) | IIIa | IIIb |
| IIIb | 13 (37.1%) | ||
| Histology | |||
| Squamous | 16 (45.7%) | ||
| Adenocarcinoma | 14 (40%) | 1 | 1 |
| Other | 5 (14.3) | ||
| Median lung function (range) | |||
| FEV1 (L) | 1.8 (0.7-3.4) | 2.7 | 3.3 |
| DLCO (% predicted) | 66.8 (26.2-102) | 83 | 88 |
| Gross tumor volume, cm3 | |||
| Median | 57.1 | Not specified | 97.4 |
| Range | 8.2-260.7 | ||
| Planning target volume, cm3 | |||
| Median | 330 | Not specified | 753.4 |
| Range | 146-807 | ||
Abbreviations: DLCO = diffusing capacity for carbon monoxide; ECOG = Eastern Cooperative Oncology Group; FEV = forced expiratory volume; PS = performance status.